Registration is open for the 2019 Chabner Colloquium: Answering the Big Questions in Cancer Research, a half-day meeting highlighting the most promising targets for the development of new cancer treatments.
DURHAM, N.C. (PRWEB) SEPTEMBER 18, 2019
Registration is open for the 2019 Chabner Colloquium: Answering the Big Questions in Cancer Research, a half-day meeting highlighting the most promising targets for the development of new cancer treatments. This live CME event is sponsored by the Society for Translational Oncology (STO) in co-providership with Massachusetts General Hospital Cancer Center and in partnership with The Oncologist. This year’s meeting will be held on November 18, 2019, at the Wyndham Boston Beacon Hill in Boston, Massachusetts.
This year’s Colloquium will feature Marcela Maus, MD, PhD, as the keynote luncheon speaker, presenting “T-cell Therapy: Moving Into New Territory”.
Promotion of the next generation of researchers is an important part of the Colloquium. To this end, the Junior Faculty Forum provides younger scientists with an opportunity to present their latest work. In addition, The Oncologist journal will present its second annual Young Investigator Award at the luncheon, following the keynote address.
“It’s a unique opportunity to share insights and perspectives between investigators and industry professionals working on novel therapeutic targets that will bring exciting changes in oncology practice in the years ahead,” said Dr. Bruce A. Chabner, Colloquium Founder and Chair.
Physician-scientists, industry professionals, and others interested in learning about advances in cancer biology leading to new approaches in clinical practice are invited to attend. To view the agenda and confirmed faculty, please visit https://sto-online.org/chabner. This year’s colloquium offers up to 5.25 AMA PRA Category 1 Credit(s)™.
About Society for Translational Oncology
STO is a 501(c)3 nonprofit professional organization dedicated to the continuing education of oncology professionals and to improvement in the quality and safety of care for cancer patients. The Society is committed to:
- Bringing knowledge and strategies for critical new developments in cancer treatment into the practice environment of the community oncologist;
- Bridging the “translational gap” between discovery and delivery of care to the patient; and
- Providing educational activities to improve physician competencies and strategies for screening, prevention, diagnosis, treatment, and management of patients with cancer.
About the Massachusetts General Hospital Cancer Center
An integral part of one of the world’s most distinguished academic medical centers, the Massachusetts General Hospital Cancer Center is among the leading cancer care providers in the United States.
U.S. News & World Report consistently ranks the Mass General Cancer Center as one of the top ten cancer centers in the country. Its nurses were the first in Massachusetts to achieve Magnet status from the American Nurses Credentialing Center in recognition of the hospital’s exceptional nursing care.
Known for providing customized, innovative treatments and compassionate care to both adults and children, the Cancer Center comprises more than 37 treatment programs within 29 fully integrated, multidisciplinary disease centers and a vast array of support and educational services. Its network of affiliations extends throughout New England and the southeastern U.S.
The Cancer Center’s commitment to eradicating cancer is fueled by scientific investigation conducted as part of one of the largest hospital-based research programs in the nation. Through a powerful synergy between laboratory scientists and bedside physicians, the Mass General Cancer Center fosters innovation in all phases of cancer research. Physician investigators conduct nearly 400 clinical trials annually.
The Massachusetts General Hospital Cancer Center is proud to be a founding member of a Harvard Medical School consortium designated by the National Cancer Institute as a comprehensive cancer center. This prestigious seven-member center forms the largest cancer research collaboration in the country. The promising new treatments developed through this partnership are revolutionizing the future of cancer medicine.
About The Oncologist
Established in 1996, this internationally peer-reviewed journal focuses on clear and concise interpretation addressing the multimodality diagnosis, treatment, and quality of life of the cancer patient. Each issue is meant to impact the practice of oncology and to facilitate significant communication in the introduction of new medical treatments and technologies. The Oncologist is the official journal of the Society for Translational Oncology (STO).
For more information, contact:
Carol Hardman, CME Manager, STO